152 related articles for article (PubMed ID: 38861890)
1. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA
Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890
[TBL] [Abstract][Full Text] [Related]
2. Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention.
Tobaruela-Resola AL; Riezu-Boj JI; Milagro FI; Mogna-Pelaez P; Herrero JI; Elorz M; Benito-Boillos A; Tur JA; Martínez JA; Abete I; Zulet MA
Nutrients; 2024 May; 16(11):. PubMed ID: 38892481
[TBL] [Abstract][Full Text] [Related]
3. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial.
Marin-Alejandre BA; Abete I; Cantero I; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Quiroga J; Martinez-Echeverria A; Uriz-Otano JI; Huarte-Muniesa MP; Tur JA; Martinez JA; Zulet MA
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31652512
[TBL] [Abstract][Full Text] [Related]
4. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial.
Marin-Alejandre BA; Cantero I; Perez-Diaz-Del-Campo N; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Quiroga J; Martinez-Echeverria A; Uriz-Otano JI; Huarte-Muniesa MP; Tur JA; Martinez JA; Abete I; Zulet MA
Liver Int; 2021 Jul; 41(7):1532-1544. PubMed ID: 33550706
[TBL] [Abstract][Full Text] [Related]
5. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
6. The Associations between Healthy Eating Patterns and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Case-Control Study.
Huang X; Gan D; Fan Y; Fu Q; He C; Liu W; Li F; Ma L; Wang M; Zhang W
Nutrients; 2024 Jun; 16(12):. PubMed ID: 38931312
[TBL] [Abstract][Full Text] [Related]
7. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
8. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.
De Nucci S; Bonfiglio C; Donvito R; Di Chito M; Cerabino N; Rinaldi R; Sila A; Shahini E; Giannuzzi V; Pesole PL; Coletta S; Lanzilotta E; Piazzolla G; Cozzolongo R; Giannelli G; De Pergola G
Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892542
[TBL] [Abstract][Full Text] [Related]
9. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
[TBL] [Abstract][Full Text] [Related]
10. Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction.
Keingeski MB; Longo L; Brum da Silva Nunes V; Figueiró F; Dallemole DR; Pohlmann AR; Vier Schmitz TM; da Costa Lopez PL; Álvares-da-Silva MR; Uribe-Cruz C
Metab Syndr Relat Disord; 2024 Jun; 22(5):394-401. PubMed ID: 38498801
[No Abstract] [Full Text] [Related]
11. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study.
Perez-Diaz-Del-Campo N; Marin-Alejandre BA; Cantero I; Monreal JI; Elorz M; Herrero JI; Benito-Boillos A; Riezu-Boj JI; Milagro FI; Tur JA; Martinez JA; Abete I; Zulet MA
Eur J Nutr; 2021 Sep; 60(6):3043-3057. PubMed ID: 33474638
[TBL] [Abstract][Full Text] [Related]
12. Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea.
Kwon YJ; Choi JE; Hong KW; Lee JW
J Transl Med; 2024 Jun; 22(1):591. PubMed ID: 38918799
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
14. Effect of a Low-Calorie Dietary Intervention on Liver Health and Body Weight in Adults with Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Overweight/Obesity: A Systematic Review and Meta-Analysis.
Dobbie LJ; Burgess J; Hamid A; Nevitt SJ; Hydes TJ; Alam U; Cuthbertson DJ
Nutrients; 2024 Apr; 16(7):. PubMed ID: 38613063
[TBL] [Abstract][Full Text] [Related]
15. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
Stefan N; Hartleb M; Popovic B; Varona R
Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
[TBL] [Abstract][Full Text] [Related]
16. Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity.
Boutari C; Stefanakis K; Simati S; Guatibonza-García V; Valenzuela-Vallejo L; Anastasiou IA; Connelly MA; Kokkinos A; Mantzoros CS
Cardiovasc Diabetol; 2024 May; 23(1):174. PubMed ID: 38762719
[TBL] [Abstract][Full Text] [Related]
17. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
[TBL] [Abstract][Full Text] [Related]
18. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
[TBL] [Abstract][Full Text] [Related]
19. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
20. Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study.
Armandi A; Bespaljko H; Mang A; Huber Y; Michel M; Labenz C; Galle PR; Neerukonda M; Bugianesi E; Schuppan D; Schattenberg JM
Aliment Pharmacol Ther; 2024 May; 59(10):1212-1222. PubMed ID: 38462919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
